The following is a comprehensive list of Yale Urology publications/presentations for the third quarter of calendar year 2025. The listing is in descending published date order and features primary faculty, trainee, and alumni work. Each item includes links to the full study or presentation and provides portions of the abstract/summary.
Li X, Gardner EE, Molina-Pinelo S, Wilhelm C, Mu P, Quintanal-Villalonga Á. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res. 2025 Sep 30. doi: 10.1038/s41422-025-01180-x. Epub ahead of print. PMID: 41023204.
In the present review, we will provide a biological and therapeutic overview of the current understanding of common and divergent molecular drivers of neuroendocrine and squamous transdifferentiation in tumors from different origins, including descriptive analysis of previously known and recently described molecular events associated with histological transformation, and propose evidence-based alternative models of transdifferentiation.
_____
Sivanesan N, Diaz GM, Tan WS, Arora S, Sprenkle PC. Comparative Analysis of Prostate Imaging Reporting and Data System and Prostate Imaging After Focal Ablation Scoring Systems in the Postfocal Therapy Assessment of Clinically Significant Prostate Cancer. Urol Pract. 2025 Oct 15:101097UPJ0000000000000899. doi: 10.1097/UPJ.0000000000000899. Epub ahead of print. PMID: 40986434.
We performed a retrospective review to analyze 59 patients who underwent FT (cryotherapy, TULSA, NanoKnife) at our institution between 2014 and 2024, all of whom obtained post treatment multiparametric MRI (mpMRI) and targeted + systematic biopsy at 1-year post treatment.
_____
Baum LVM, Soulos PR, Kc M, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Liberatore M, Leapman MS, Jairam V, Dinan MA, Gross CP, Park HS. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Cancer. 2025 Oct 1;131(19):e70027. doi: 10.1002/cncr.70027. PMID: 40977160; PMCID: PMC12451255.
This study sought to determine trends in opioid prescribing by clinical stratum and pain for patients with cancer from 2016 to 2020.
_____
Palencia PS, Smani S, Zhao X, Kandala K, Sivanesan N, Cavallo JA, Roessler N, Aneja S, An Y, Miszczyk M, Leapman MS. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiother Oncol. 2025 Sep 21;213:111158. doi: 10.1016/j.radonc.2025.111158. Epub ahead of print. PMID: 40987387.
Within the National Cancer Database (2004-2020), we identified individuals with de-novo metastatic PCa treated with hormonal therapy (HT) with or without prostate RT. Kaplan-Meier curves and multivariable proportional hazard regression models were used to compare overall survival (OS) across nodal (M1a), bone (M1b), and visceral (M1c) disease, using propensity score matched (PSM) samples.
_____
Sivanesan N, Diaz GM, Strachan S, Kandala K, Zhao X, Tan WS, Leapman MS, Sprenkle PC. MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer. Curr Probl Cancer. 2025 Sep 13;59:101251. doi: 10.1016/j.currproblcancer.2025.101251. Epub ahead of print. PMID: 40946534.
To evaluate whether perineural invasion independently predicts Gleason score upgrading during active surveillance in patients undergoing MRI-US fusion biopsy.
_____
Rabil MJ, Choksi AU, Leapman MS. Harmonizing environmental and economic forces in urologic care. Curr Opin Urol. 2025 Nov 1;35(6):679-684. doi: 10.1097/MOU.0000000000001338. Epub 2025 Sep 12. PMID: 40948360.
In this review, we examine strategies that seek to align environmental and economic forces in urologic care delivery within a market-influenced healthcare system.
_____
Roessler N, Miszczyk M, Matsukawa A, Dematteis A, Alfarhan AR, Cormio A, Alqahtani AS, Rajwa P, Schuettfort VM, Vetterlein MW, Soeterik TFW, Fazekas T, Fisch M, Leapman MS, Karakiewicz PI, Shariat SF. Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2025 Sep 8;80:48-56. doi: 10.1016/j.euros.2025.08.008. PMID: 40994543; PMCID: PMC12454867.
This meta-analysis evaluates the impact of PARPi agents on health-related quality of life (HRQoL) using data from prospective trials.
_____
Lokeshwar SD, Choksi AU, Smani S, Heacock D, Kanaparthy NS, Shaheen DM, Dashevsky M, Martin T, Singh D, Motamedinia P, Sangal RB. A Novel Electronic Health Record-Integrated Clinical Pathway for Nephrolithiasis: Development and Management Outcomes. Urol Pract. 2025 Sep;12(5):603-612. doi: 10.1097/UPJ.0000000000000847. Epub 2025 Jun 3. PMID: 40459510.
We aimed to enhance pain control, streamline discharge practices, and optimize overall ED patient care. This study evaluates the impact of this pathway on important nephrolithiasis management process measures.
_____
Rabil MJ, Jalfon M, Palencia P, Heckscher D, Kong V, Golos A, Richmond R, Chess A, Kim IY, Leapman MS, Cavallo JA. Automated electronic medical record abstraction algorithm for radical prostatectomy outcomes. Urol Oncol. 2025 Aug 29:S1078-1439(25)00286-8. doi: 10.1016/j.urolonc.2025.07.028. Epub ahead of print. PMID: 40885622.
We hypothesized that a novel electronic medical record (EMR)-based, automated algorithm-driven algorithm for surgical outcomes and quality metrics following robot-assisted laparoscopic radical prostatectomy (RALP) would demonstrate >90% sensitivity and specificity and significant inter-rater reliability (IRR) with National Surgical Quality Improvement Program (NSQIP) abstraction.
_____
Ward BL, Zhang AY, Leapman MS, Cavallo JA, Kim IY. Early Continence and Erectile Function Recovery Following Transvesical Single-Port Robot-Assisted Radical Prostatectomy: Initial Single Institution Experience. Cancers (Basel). 2025 Aug 27;17(17):2793. doi: 10.3390/cancers17172793. PMID: 40940891; PMCID: PMC12427196.
We aimed to evaluate early functional and oncologic outcomes following SP-TV-RARP at a single academic institution.
_____
Choksi AU, Smani S, Lokeshwar SD, Sundaresan VM, Hayden CS, Segal DA, Kellner DS. Shifts in clinical practice and patient demographics following the introduction of holmium laser enucleation for benign prostatic hyperplasia in a general urology clinic. J Biol Methods. 2025 Aug 20;12(3):e99010069. doi: 10.14440/jbm.2025.0002. PMID: 40937374; PMCID: PMC12422107.
This study evaluated how the adoption of HoLEP in a general urology clinic influenced clinical and procedural volume.
_____
Makarov DV, Thomas JK, Ciprut S, Rivera AJ, Sherman SE, Braithwaite RS, Best SL, Blakely S, D'Agostino LA, Dahm P, Dash A, Leapman MS, Leppert JT, Sanchez A, Shelton JB, Tessier CD, Tenner CT, Gold HT, Shedlin MG, Zeliadt SB. Prostate Cancer Imaging Stewardship: a multi-modal, physician-centered intervention for guideline-concordant imaging. J Natl Cancer Inst. 2025 Aug 11:djaf210. doi: 10.1093/jnci/djaf210. Epub ahead of print. PMID: 40796156.
Inappropriate imaging to stage low-risk prostate cancer is considered low-value care. Determining the effectiveness of a theory-based intervention, Prostate Cancer Imaging Stewardship (PCIS), to promote guideline-concordant imaging.
_____
Du Y, Onofrey JA, Dvornek NC. Multi-View and Multi-Scale Alignment for Contrastive Language-Image Pre-training in Mammography. Inf Process Med Imaging. 2026;15830:247-262. doi: 10.1007/978-3-031-96625-5_17. Epub 2025 Aug 7. PMID: 40995617; PMCID: PMC12456755.
Here, we propose one of the first adaptations of the full CLIP model to mammography, which presents significant challenges due to labeled data scarcity, high-resolution images with small regions of interest, and class-wise imbalance.
_____
Smani S, Wang R, Zhou X, Sprenkle PC, Kim IY, Dinan M, Gross CP, Ma X, Leapman MS. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology. 2025 Aug 5:S0090-4295(25)00751-4. doi: 10.1016/j.urology.2025.07.070. Epub ahead of print. PMID: 40759400.
To better characterize patterns of prostate magnetic resonance imaging (MRI) use in the United States, we assessed the association between area-level sociodemographic factors and receipt of prostate MRI prior to biopsy.
_____
Palencia PS, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J, Sridhar A, Kelly JD, Lee BH, Kamat AM, Tan WS. Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers. 2025; 17(15):2562. https://doi.org/10.3390/cancers17152562
In this review, we discuss the current literature on partial cystectomy, indications, patient selection, initial workup, surgical approach and the role of systemic therapy. We also compare complications, cancer outcomes and quality of life between patients treated with partial cystectomy and complete bladder removal (radical cystectomy).
_____
Zurl H, Korn SM, Pohl KK, Qian Z, Piccolini A, Iyer HS, Leapman MS, Ahyai S, Shariat SF, Trinh QD, Thiel CL, Loeb S, Cole AP. Estimating the Carbon Emissions of a Single Prostate-specific Antigen Test: Results from a Cradle-to-grave Life Cycle Assessment. Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00211-1. doi: 10.1016/j.euf.2025.07.006. Epub ahead of print. PMID: 40753028.
We aimed to evaluate the environmental impact of a highly common but controversial urology-specific blood test: the prostate-specific antigen (PSA) test.
_____
Shinder BM, Meng L, Singer EA. Harnessing the power of combination therapy: reflecting on the final survival data from the CLEAR study with lenvatinib plus pembrolizumab. Transl Androl Urol. 2025 Aug 30;14(8):2124-2128. doi: 10.21037/tau-2025-201. Epub 2025 Aug 26. PMID: 40949457; PMCID: PMC12433167.
The CLEAR study demonstrated a significantly higher objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) with lenvatinib plus pembrolizumab compared to sunitinib alone in patients with untreated aRCC.
_____
Rahman SN, Martin DT, Keervani K, James S, Humphrey P, Hesse D, Tan WS, Patel S, Wright J, Ghali F. Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer. Cancers (Basel). 2025 Jul 31;17(15):2536. doi: 10.3390/cancers17152536. PMID: 40805235; PMCID: PMC12346734.
The therapeutic benefits of LND for variant subtype bladder cancer (VBC), a heterogenous and distinct set of diseases, are not well established. We aim to characterize the impact of LND on overall survival across VBC subtypes.
_____
Cahill EM, de Oca EMM, Flores JM, Bennett NE, Mulhall JP. Knowledge and Attitudes Towards Fertility Preservation in Patients Undergoing Radical Prostatectomy. Urology. 2025 Jul 11:S0090-4295(25)00684-3. doi: 10.1016/j.urology.2025.07.007. Epub ahead of print. PMID: 40652988.
To better understand the fertility discussion experience and attitudes regarding the fertility of men undergoing radical prostatectomy (RP).
_____
Smani S, Lokeshwar SD, Jalfon M, Heckscher D, Press BH, Heacock D, Leapman MS, Kenney P, Ghali F. Development and Utilization of a Novel Electronic Health Record-Based Care Pathway for Nonmuscle Invasive Bladder Cancer. Urol Pract. 2025 Jul 10:101097UPJ0000000000000872. doi: 10.1097/UPJ.0000000000000872. Epub ahead of print. PMID: 40637707.
We aimed to develop an electronic health record (EHR)-integrated intervention to improve compliance with clinical guidelines for the management of NMIBC.
_____
DuBois J, Smani S, Golos A, Rivera Lopez C, Lokeshwar SD. Micro-Ultrasound in the Detection of Clinically Significant Prostate Cancer: A Comprehensive Review and Comparison with Multiparametric MRI. Tomography. 2025 Jul 8;11(7):80. doi: 10.3390/tomography11070080. PMID: 40710898; PMCID: PMC12299324.
This review evaluates whether the evidence base for micro-US meets thresholds comparable to those that led to MRI's guideline adoption, synthesizes diagnostic performance data compared to mpMRI, and outlines future research priorities to define its clinical role.
_____
Roessler, N., Miszczyk, M., Dematteis, A., Zattoni, F., Fazekas, T., Carletti, F., … [Leapman MS] Jereczek-Fossa, B. A. (2025). Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. Clinical and Translational Radiation Oncology., 54. https://doi.org/10.1016/j.ctro.2025.101009
In this prospectively registered systematic review and meta-analysis (CRD42025648251), we searched MEDLINE, Scopus, CENTRAL, and Google Scholar in March 2025 for phase 3 RCTs evaluating the addition of RT to systemic therapy to improve OS in mHSPC patients. Hazard ratios (HRs) were pooled using random-effects meta-analysis. Risk of Bias was assessed with Cochrane’s RoB 2 tool.
_____
Kinney AY, An J, Lin Y, Tundealao S, Saraiya B, Lu SE, Guest DD, Harding EM, Amorim F, Heidt E, Arana-Chicas E, Chen C, Boyce T, Kim IY, Arap W, Blair CK, Irwin MR. Project HERO: a randomized trial of Tai Chi qigong versus intensity-matched exercise and usual care for fatigue in older male cancer survivors. BMC Complement Med Ther. 2025 Jul 4;25(1):239. doi: 10.1186/s12906-025-04988-7. PMID: 40616105; PMCID: PMC12228344.
We compared the efficacy of Tai Chi Qigong (TCQ) versus exercise intensity-matched (EIM) and usual care in older, male cancer survivors with fatigue.
_____
Greenberg, J.W., Lai, W.R., Sanekommu, G., Thomas, R. (2025). Complications and Management of Robotic Lower Urinary Tract Procedures. In: Su, LM., Joseph, J.P., Bayne, C.E. (eds) The Comprehensive Atlas of Robotic Urologic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-031-72305-6_38
This chapter reviews the complications associated with robotic surgical procedures, especially those related to patient positioning as well as intraoperative and postoperative adverse events, and discusses management strategies.
_____
Sundaresan VM, Leapman MS. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Semin Radiat Oncol. 2025 Jul;35(3):385-392. doi: 10.1016/j.semradonc.2025.05.001. PMID: 40516973.
In this article, we distill five evidence-based arguments that commonly motivate patients to select radical prostatectomy as initial treatment of 'high-risk' prostate cancer.
_____
Band EM, Quintanilla V. Urologic Care, Spanning All Ages, Genders, and Races. Physician Assistant Clinics, Volume 10, Issue 3, 2025, Pages xv-xvi, ISSN 2405-7991, ISBN 9780443293580, https://doi.org/10.1016/j.cpha.2025.02.001.
This issue of Physician Assistant Clinics—Urology looks to discuss the urologic system and highlights treatment and preventative measures for the broad spectrum of disease processes.
_____
Mirasol J, Choksi A. End-Stage Renal Disease and Renal Transplantation: Causes of End-stage Renal Disease, Complications, Outcomes, Medical Management, Renal Transplantation, and Urologic Considerations. Physician Assistant Clinics, Volume 10, Issue 3, 2025, Pages 513-532, https://doi.org/10.1016/j.cpha.2025.01.010.
Kidney transplantation provides significant survival benefits and improvement in quality of life for the treatment of ESKD compared to dialysis. Overall survival has progressively improved over the years.
_____
Band ME, Quintanilla V. Urology. Physician Assistant Clinics, Volume 10, Issue 3, 2025, Page i, https://doi.org/10.1016/S2405-7991(25)00029-5.
###